Investor Overview

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Quote

Recent News

Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Third Quarter 2018 Financial Results
Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of
Toggle Summary Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
MENLO PARK, Calif. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report
Toggle Summary Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Topline efficacy and safety results anticipated by early April 2019     MENLO PARK, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today

Upcoming Events

There are currently no events to display.

Copyright West LLC. Minimum 15 minutes delayed.